Analysis for BDX

📈 Growth & Financial Trajectory

Eight quarters show a generally flat revenue footprint around $5.0B with modest quarterly swings. From start of the window (2024 Q4) to end (2026 Q3), revenue is essentially flat (~-0.1%). Net income declined from about $487M to $377M, with a mid-year dip to a loss of $311M in 2026 Q2 before rebounding in Q3. Gross margins stayed in the mid-40s%, and operating margins hovered in the low-teens, signaling resilient profitability despite earnings volatility.

💰 Margins & Cash Flow

Gross margin trended in the mid-40s% range; operating margin generally around 10–14%. Net income fluctuated quarter-to-quarter, but cash flow from operating activities remained robust, typically around $0.6–0.8B per quarter (e.g., Q3 2026: $651M; Q2 2026: $598M). Investing and financing cash flows were negative in several periods, implying ongoing investment activity, but the company generated solid operating cash flow to support activities and returns. Overall margins and cash flow profile remain healthy, with volatility driven more by quarterly earnings mix than by cash generation.

🛡️ Balance Sheet & Liquidity

Total assets run around $54–55B, with equity near $25–28B and liabilities near $29–30B. Current assets vs current liabilities is sometimes tight (e.g., 2026 Q3: current assets $8.14B vs current liabilities $9.40B), indicating modest near-term liquidity risk but a strong, asset-rich balance sheet. Long-term leverage remains moderate, supported by ample noncurrent assets and positive operating cash flow across quarters.

⚠️ Key Drivers & Risks

• Drivers: Global healthcare demand and large installed base; ongoing product refresh cycles support revenue stability and margin.
• Risks: Earnings volatility from quarterly timing and cost pressures; cyclicality of hospital spending and exposure to regulatory/currency shifts can impact near-term earnings and valuation.